March 23, 2021
Adding ibalizumab to optimized background therapy appears cost-effective for adults with multidrug-resistant HIV-1 infection, according to a study published in PharmacoEconomics.
Conducted by researchers from RTI Health Solutions and Georgetown University, the analysis considered the cost-effectiveness and budget impact of using ibalizumab, a first-in-class, long-acting, postattachment HIV-1 inhibitor, in the difficult-to-treat population. The study used a Markov model, with data from ibalizumab clinical trials, market uptake projections, and published literature, to follow patients with multidrug-resistant HIV-1 infection through two final lines of antiretroviral therapy: ibalizumab plus optimized background therapy or optimized background therapy alone, followed by nonsuppressive therapy.
Compared with optimized background therapy alone, patients who received ibalizumab plus optimized background therapy lived longer, healthier lives, according to the study. The incremental cost of ibalizumab was $133,040 per quality-adjusted life-year gained.
For a hypothetical commercial health plan with 1 million members, the introduction of ibalizumab over 3 years was estimated to increase the budget by $217,260 the first year, $385,245 the second year, and $560,310 the third year. Per member per month, the increases worked out to $0.018 the first year, $0.032 the second year, and $0.047 the third year, according to the study.
“Ibalizumab may represent a cost-effective and affordable option to improve health outcomes for individuals with multidrug-resistant HIV-1 infection,” researchers concluded.
Brogan AJ, Talbird SE, Davis AE, La EM, Kumar PN. The Cost-Effectiveness and Budget Impact of Ibalizumab-uiyk for Adults with Multidrug-Resistant HIV-1 Infection in the United States [published online ahead of print, 2021 Feb 3]. Pharmacoeconomics. 2021;10.1007/s40273-020-00992-6. doi:10.1007/s40273-020-00992-6